Biosensor Europe

Biosensors International is a global medical device company specializing in the development and commercialization of innovative products for interventional cardiology and critical care. The company is a pioneer in the field of drug-eluting stents, notably developing the BioMatrix and BioFreedom product lines which feature the proprietary anti-restenotic drug Biolimus A9. Biosensors Europe SA serves as the regional headquarters for Europe, the Middle East, and Africa, managing clinical trials and commercial operations from its base in Switzerland. In 2018, the company was fully acquired by Blue Sail Medical, a major Chinese medical products manufacturer, to expand its global footprint in the cardiovascular market.